3,206
Views
32
CrossRef citations to date
0
Altmetric
Review Article

Collagenase Clostridium histolyticum: emerging practice patterns and treatment advances

, , , &
Pages 251-261 | Received 25 Mar 2015, Accepted 24 Jan 2016, Published online: 06 Apr 2016

References

  • Black EM, Blazar PE. Dupuytren disease: an evolving understanding of an age-old disease. J Am Acad Orthop Surg 2011;19:746–57.
  • Rayan GM. Dupuytren disease: anatomy, pathology, presentation, and treatment. J Bone Joint Surg Am 2007;89:189–98.
  • Shaw RB Jr., Chong AK, Zhang A, et al. Dupuytren's disease: history, diagnosis, and treatment. Plast Reconstr Surg 2007;120:44e–54e.
  • Bayat A, McGrouther DA. Management of Dupuytren's disease-clear advice for an elusive condition. Ann R Coll Surg Engl 2006;88:3–8.
  • Hobby JL, Dias JJ. A review of hand surgery provision in England. J Hand Surg Br 2006;31:230–5.
  • Pratt AL, Byrne G. The lived experience of Dupuytren's disease of the hand. J Clin Nurs 2009;18:1793–802.
  • Hindocha S, McGrouther DA, Bayat A. Epidemiological evaluation of Dupuytren's disease incidence and prevalence rates in relation to etiology. Hand (NY) 2009;4:256–69.
  • Hart MG, Hooper G. Clinical associations of Dupuytren's disease. Postgrad Med J 2005;81:425–8.
  • Wilbrand S, Ekbom A, Gerdin B. The sex ratio and rate of reoperation for Dupuytren's contracture in men and women. J Hand Surg Br 1999;24:456–9.
  • Gudmundsson KG, Arngrimsson R, Sigfusson N, et al. Epidemiology of Dupuytren's disease: clinical, serological, and social assessment. The Reykjavik study. J Clin Epidemiol 2000;53:291–6.
  • Hoèt F, Boxho J, Decoster E, et al. [Dupuytren's disease. Review of 326 surgically treated patients]. Ann Chir Main 1988;7:251–5.
  • Saboeiro AP, Porkorny JJ, Shehadi SI, et al. Racial distribution of Dupuytren's disease in Department of Veterans Affairs patients. Plast Reconstr Surg 2000;106:71–5.
  • Arkkila PE, Kantola IM, Viikari JS. Dupuytren's disease: association with chronic diabetic complications. J Rheumatol 1997;24:153–9.
  • Aydeniz A, Gursoy S, Guney E. Which musculoskeletal complications are most frequently seen in type 2 diabetes mellitus? J Int Med Res 2008;36:505–11.
  • Noble J, Heathcote JG, Cohen H. Diabetes mellitus in the aetiology of Dupuytren's disease. J Bone Joint Surg Br 1984;66:322–5.
  • Arafa M, Noble J, Royle SG, et al. Dupuytren's and epilepsy revisited. J Hand Surg Br 1992;17:221–4.
  • Critchley EM, Vakil SD, Hayward HW, Owen VM. Dupuytren's disease in epilepsy: result of prolonged administration of anticonvulsants. J Neurol Neurosurg Psychiatry 1976;39:498–503.
  • Burge P, Hoy G, Regan P, Milne R. Smoking, alcohol and the risk of Dupuytren's contracture. J Bone Joint Surg Br 1997;79:206–10.
  • Godtfredsen NS, Lucht H, Prescott E, et al. A prospective study linked both alcohol and tobacco to Dupuytren's disease. J Clin Epidemiol 2004;57:858–63.
  • Bovenzi M. Hand-arm vibration syndrome: diagnostic aspects, dose-response relationship and exposure limits. Med Lav 1994;85:463–73.
  • Cocco PL, Frau P, Rapallo M, Casula D. Occupational exposure to vibration and Dupuytren's disease: a case-controlled study. Med Lav 1987;78:386–92.
  • Liss GM, Stock SR. Can Dupuytren's contracture be work-related?: review of the evidence. Am J Ind Med 1996;29:521–32.
  • Thomas PR, Clarke D. Vibration white finger and Dupuytren's contracture: are they related? Occup Med (Lond) 1992;42:155–8.
  • Bayat A, Walter J, Lambe H, et al. Identification of a novel mitochondrial mutation in Dupuytren's disease using multiplex DHPLC. Plast Reconstr Surg 2005;115:134–41.
  • McCarty S, Syed F, Bayat A. Role of the HLA system in the pathogenesis of Dupuytren's disease. Hand (NY) 2010;5:241–50.
  • Dolmans GH, Werker PM, Hennies HC, et al. Wnt signaling and Dupuytren's disease. N Engl J Med 2011;365:307–17.
  • Witthaut J, Jones G, Skrepnik N, et al. Efficacy and safety of collagenase clostridium histolyticum injection for Dupuytren contracture: short-term results from 2 open-label studies. J Hand Surg Am 2013;38:2–11.
  • Hurst LC, Badalamente MA, Hentz VR, et al. Injectable collagenase clostridium histolyticum for Dupuytren's contracture. N Engl J Med 2009;361:968–79.
  • Gilpin D, Coleman S, Hall S, et al. Injectable collagenase Clostridium histolyticum: a new nonsurgical treatment for Dupuytren's disease. J Hand Surg Am 2010;35:2027–38.
  • Peimer CA, Skodny P, Mackowiak JI. Collagenase clostridium histolyticum for dupuytren contracture: patterns of use and effectiveness in clinical practice. J Hand Surg Am 2013;38:2370–6.
  • Hueston JT. Enzymic fasciotomy. Hand 1971;3:38–40.
  • Gabbiani G, Majno G. Dupuytren's contracture: fibroblast contraction? An ultrastructural study. Am J Pathol 1972;66:131–46.
  • Tomasek JJ, Schultz RJ, Episalla CW, Newman SA. The cytoskeleton and extracellular matrix of the Dupuytren's disease “ myofibroblast”: an immunofluorescence study of a nonmuscle cell type. J Hand Surg Am 1986;11:365–71.
  • Tomasek JJ, Schultz RJ, Haaksma CJ. Extracellular matrix-cytoskeletal connections at the surface of the specialized contractile fibroblast (myofibroblast) in Dupuytren disease. J Bone Joint Surg Am 1987;69:1400–7.
  • Badalamente MA, Stern L, Hurst LC. The pathogenesis of Dupuytren's contracture: contractile mechanisms of the myofibroblasts. J Hand Surg Am 1983;8:235–43.
  • Magro G, Lanzafame S, Micali G. Co-ordinate expression of alpha 5 beta 1 integrin and fibronectin in Dupuytren's disease. Acta Histochem 1995;97:229–33.
  • Hindocha S, Iqbal SA, Farhatullah S, et al. Characterization of stem cells in Dupuytren's disease. Br J Surg 2011;98:308–15.
  • Luck JV. Dupuytren's contracture; a new concept of the pathogenesis correlated with surgical management. J Bone Joint Surg Am 1959;41:635–64.
  • Badalamente MA, Sampson SP, Hurst LC, et al. The role of transforming growth factor beta in Dupuytren's disease. J Hand Surg Am 1996;21:210–15.
  • Brickley-Parsons D, Glimcher MJ, Smith RJ, et al. Biochemical changes in the collagen of the palmar fascia in patients with Dupuytren's disease. J Bone Joint Surg Am 1981;63:787–97.
  • Meyerding H, Black J, Broders A. The etiology and pathology of Dupuytren's contracture. Surg Gynecol Obstetr 1941;72:582–90.
  • Hinz B. Formation and function of the myofibroblast during tissue repair. J Invest Dermatol 2007;127:526–37.
  • Bailey AJ, Sims TJ, Gabbiani G, et al. Collagen of Dupuytren's disease. Clin Sci Mol Med 1977;53:499–502.
  • Bazin S, Le Lous M, Duance VC, et al. Biochemistry and histology of the connective tissue of Dupuytren's disease lesions. Eur J Clin Invest 1980;10:9–16.
  • Gelberman RH, Amiel D, Rudolph RM, Vance RM. Dupuytren's contracture. An electron microscopic, biochemical, and clinical correlative study. J Bone Joint Surg Am 1980;62:425–32.
  • Menzel EJ, Piza H, Zielinski C, et al. Collagen types and anticollagen-antibodies in Dupuytren's disease. Hand 1979;11:243–8.
  • Bode W. A helping hand for collagenases: the haemopexin-like domain. Structure 1995;3:527–30.
  • Klein T, Bischoff R. Physiology and pathophysiology of matrix metalloproteases. Amino Acids 2011;41:271–90.
  • Weinberg M, Randin A. Ferment fibrolytique d'origine microbienne. Compt Rend Soc Biol 1931;107:27–8.
  • Weinberg M, Randin A. Propriétés physioco-chimiques du ferment fibrolytique d'origine microbienne. Compt Rend Soc Biol 1932;110:352–3.
  • Ssadikow W. Über ein neues Kollagen-lösendes Ferment (Kollagenase). Biochem Z 1927;181:267–83.
  • Starkweather KD, Lattuga S, Hurst LC, et al. Collagenase in the treatment of Dupuytren's disease: an in vitro study. J Hand Surg Am 1996;21:490–5.
  • Briefing document for collagenase clostridium histolyticum (AA4500) in the treatment of advanced Dupuytren's disease [http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/ucm182012.html], 2009.
  • Syed F, Thomas AN, Singh S, et al. In vitro study of novel collagenase (XIAFLEX®) on Dupuytren's disease fibroblasts displays unique drug related properties. PLoS One 2012;7:e31430.
  • Badalamente MA, Hurst LC. Efficacy and safety of injectable mixed collagenase subtypes in the treatment of Dupuytren's contracture. J Hand Surg Am 2007;32:767–74.
  • Raven RB, 3rd, Kushner H, Nguyen D, et al. Analysis of efficacy and safety of treatment with Collagenase Clostridium histolyticum among subgroups of patients with Dupuytren contracture. Ann Plast Surg 2014;73:286–90.
  • Bainbridge C, Gerber RA, Szczypa PP, et al. Efficacy of collagenase in patients who did and did not have previous hand surgery for Dupuytren's contracture. J Plast Surg Hand Surg 2012;46:177–83.
  • Peimer C, Blazar P, Coleman S, et al. Dupuytren contracture recurrence following treatment with Collagenase Clostridium histolyticum (CORDLESS Collagenase Option for Reduction of Dupuytren Long-Term Evaluation of Safety Study): 5-Year data. J Hand Surg (Am) 2015;40:1597–605.
  • Peimer CA, McGoldrick CA, Greg Kaufman G. Nonsurgical treatment of Dupuytren contracture: 3-year safety results using Collagenase Clostridium histolyticum. J Hand Surg 2013;38:e52.
  • Rodriguez JR, Zhang W, Scammell BE, Davis TRC. Dynamism in Dupuytren’s contractures. J Hand Surg 2015;40E:166–70.
  • Coleman S, Gilpin D, Kaplan FT, et al. Efficacy and safety of concurrent collagenase clostridium histolyticum injections for multiple Dupuytren contractures. J Hand Surg Am 2014;39:57–64.
  • Verhayden JR. Early outcomes of a sequential series of 144 patient with Dupuytren's disease treated by collagenase injection using an increased dose, multicord technique. J Hand Surg 2015;40:133–40.
  • Kaplan TD, Badalamente M, Hurst L, et al. Delayed manipulation following Clostridial Collagenase histolyticum injection for Dupuytren contracture. J Hand Surg 2013;38:52–3.
  • Mickelson DT, Noland SS, Watt AJ, et al. Prospective RCT comparing 1-versus 7-day manipulation following collagenase injection for Dupuytren contracture. J Hand Surg(Am) 2014;39:1933–41.
  • Kemler MA, Houpt P, van der Horst CM. A pilot study assessing the effectiveness of postoperative splinting after limited fasciectomy for Dupuytren's disease. J Hand Surg Eur Vol 2012;37:733–7.
  • Larson D, Jerosch-Herold C. Clinical effectiveness of post-operative splinting after surgical release of Dupuytren's contracture: a systematic review. BMC Musculoskelet Disord 2008;9:104.
  • Warwick D, Arner M, Pajardi G, et al. Collagenase Clostridium histolyticum in patients with Dupuytren's contracture: results from POINT X, an open-label study of clinical and patient-reported outcomes. J Hand Surg 2015;40E:142–32.
  • Hay DC, Louie DL, Earp BE, et al. Surgical findings in the treatment of Dupuytren’s disease after initial treatment with clostridial collagenase. J Hand Surg 2014;39E:463–5.
  • Edmunds I, Avakian Z. Hand surgery on anticoagulated patients: a prospective study of 121 operations. Hand Surg 2010;15:109–13.
  • Au-Yong IT, Wildin CJ, Dias JJ, Page RE. A review of common practice in Dupuytren surgery. Tech Hand up Extrem Surg 2005;9:178–87.
  • Engstrand C, Boren L, Liedberg GM. Evaluation of activity limitation and digital extension in Dupuytren's contracture three months after fasciectomy and hand therapy interventions. J Hand Ther 2009;22:221–6.
  • Draviaraj KP, Chakrabarti I. Functional outcome after surgery for Dupuytren's contracture: a prospective study. J Hand Surg Am 2004;29:804–8.
  • Crean SM, Gerber RA, Le Graverand MP, et al. The efficacy and safety of fasciectomy and fasciotomy for Dupuytren's contracture in European patients: a structured review of published studies. J Hand Surg Eur 2011;36:396–407.
  • Figus A, Britto JA, Ragoowansi RH, Elliot D. A clinical analysis of Dupuytren's disease of the thumb. J Hand Surg Eur 2008;33:272–9.
  • Milner RH. Dupuytren's disease affecting the thumb and first web of the hand. J Hand Surg Br 2003;28:33–6.
  • Bendon CL, Giele HP. Collagenase for Dupuytren's disease of the thumb. J Bone Joint Surg Br 2012;94:1390–2.